NO20011555L - Orale doseringsformuleringer omfattende (2S,3S,5R)-2-(3,5- difluorfenyl)-3,5-dimetyl-2-morfolinol og en effektivstabiliserende mengde alginsyre - Google Patents

Orale doseringsformuleringer omfattende (2S,3S,5R)-2-(3,5- difluorfenyl)-3,5-dimetyl-2-morfolinol og en effektivstabiliserende mengde alginsyre

Info

Publication number
NO20011555L
NO20011555L NO20011555A NO20011555A NO20011555L NO 20011555 L NO20011555 L NO 20011555L NO 20011555 A NO20011555 A NO 20011555A NO 20011555 A NO20011555 A NO 20011555A NO 20011555 L NO20011555 L NO 20011555L
Authority
NO
Norway
Prior art keywords
morpholinol
difluorophenyl
dimethyl
alginic acid
oral dosage
Prior art date
Application number
NO20011555A
Other languages
English (en)
Other versions
NO20011555D0 (no
Inventor
Samuel Bruce Balik
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20011555D0 publication Critical patent/NO20011555D0/no
Publication of NO20011555L publication Critical patent/NO20011555L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Det er beskrevet adskilte orale doseringsformer, typisk tabletter eller kapsler, inneholdende (2S,3S,5R)-2-(3,5-difluorfenyl)-3,5-dimetyl-2-morfolinol eller et fysiologisk akseptabelt salt eller solvat derav, eller et solvat av nevnte salt, og en effektiv stabiliserende mengde alginsyre. Disse doseringsformene er nyttige for forhindring eller behandling av manglende oppmerksomhetshyperkinetikk- forstyrrelse eller depresjon, eller for behandling av avhengighet av nikotin- inneholdende produkter, spesielt tobakkinneholdende produkter, så som behjelpe opphør av røking.
NO20011555A 1998-09-28 2001-03-27 Orale doseringsformuleringer omfattende (2S,3S,5R)-2-(3,5- difluorfenyl)-3,5-dimetyl-2-morfolinol og en effektivstabiliserende mengde alginsyre NO20011555L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10211298P 1998-09-28 1998-09-28
PCT/EP1999/007117 WO2000018406A1 (en) 1998-09-28 1999-09-24 Oral dosage formulations comprising (2s,3s,5r) -2-(3,5- difluorophenyl) -3,5-dimethyl -2-morpholinol and an effective stabilizing amount of alginic acid

Publications (2)

Publication Number Publication Date
NO20011555D0 NO20011555D0 (no) 2001-03-27
NO20011555L true NO20011555L (no) 2001-03-27

Family

ID=22288187

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20011555A NO20011555L (no) 1998-09-28 2001-03-27 Orale doseringsformuleringer omfattende (2S,3S,5R)-2-(3,5- difluorfenyl)-3,5-dimetyl-2-morfolinol og en effektivstabiliserende mengde alginsyre

Country Status (17)

Country Link
EP (1) EP1117407A1 (no)
JP (1) JP2002525328A (no)
KR (1) KR20010075385A (no)
CN (1) CN1328459A (no)
AR (1) AR022673A1 (no)
AU (1) AU6087399A (no)
BR (1) BR9914096A (no)
CA (1) CA2345638A1 (no)
CZ (1) CZ20011142A3 (no)
HU (1) HUP0103459A2 (no)
IL (1) IL142054A0 (no)
MA (1) MA26693A1 (no)
NO (1) NO20011555L (no)
PE (1) PE20001087A1 (no)
PL (1) PL346877A1 (no)
TR (1) TR200100863T2 (no)
WO (1) WO2000018406A1 (no)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7750100A (en) * 1999-10-13 2001-04-23 Glaxo Group Limited Method for the treatment of obesity
DE102008047910A1 (de) 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tablettierhilfsstoff auf Laktose- und Cellulosebasis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4597969A (en) * 1982-04-05 1986-07-01 Merck Sharp & Dohme Stabilization of unstable drugs or food supplements
GB8924528D0 (en) * 1989-10-31 1989-12-20 Wellcome Found Heterocyclic pharmaceutical compounds,preparation and use

Also Published As

Publication number Publication date
PL346877A1 (en) 2002-03-11
KR20010075385A (ko) 2001-08-09
CN1328459A (zh) 2001-12-26
JP2002525328A (ja) 2002-08-13
NO20011555D0 (no) 2001-03-27
BR9914096A (pt) 2001-07-31
EP1117407A1 (en) 2001-07-25
CA2345638A1 (en) 2000-04-06
AR022673A1 (es) 2002-09-04
TR200100863T2 (tr) 2001-07-23
AU6087399A (en) 2000-04-17
IL142054A0 (en) 2002-03-10
PE20001087A1 (es) 2000-10-20
WO2000018406A1 (en) 2000-04-06
CZ20011142A3 (cs) 2001-09-12
MA26693A1 (fr) 2004-12-20
HUP0103459A2 (hu) 2002-01-28

Similar Documents

Publication Publication Date Title
BE2011C013I2 (no)
MXPA02006780A (es) Formas de dosis de bencimidazol substituido novedosas y metodo para usar las mismas.
SE8804629A (no)
NO20003051D0 (no) Metode for administrering av AspB28-humant insulin
EE04463B1 (et) 3-arüülpropaanhappe derivaadid ja nende analoogid, nende valmistamise meetod, neid sisaldavad ravimkoostised ja ühendid kasutamiseks ravis
UA63993C2 (uk) Фармацевтична лікарська форма, що швидко тане в роті (варіанти) та спосіб формування гранул
NO332857B1 (no) Inhalasjonskapsel samt anvendelse av slike
SE0102276D0 (sv) Device and method for the administration of a medicament
PL333524A1 (en) Improved prolonged release pharmaceutic preparation for administration of nephadosone, oral dosage form thereof and improved nephadosone administration method
WO2001080837A3 (de) Transdermale oder transmucosale darreichungsformen mit einer nicotinhaltigen wirkstoffkombination zur raucherentwöhnung
DK140393A (da) Ioderet uracilnicleosid, denne forbindelse til anvendelse mod en adenovirusinfektion, anvendelse af forbindelsen til fremstilling af et lægemiddel mod en adenovirusinfektion, farmaceutisk præparater indeholdende forbindelsen samt fremgangsmåde til fremstilling af forbindelsen
NZ514129A (en) Tolperison-containing, pharmaceutical preparation for oral administration
FR2771292B1 (fr) Spheroides contenant de la tiagabine, procede de preparation et compositions pharmaceutiques
MXPA04003346A (es) Formulacion de dosis oral de disolucion instantanea.
GR3015014T3 (en) Compositions for topical administration containing fluticasone propionate and oxiconazole or its salts.
YU242789A (en) New compound, 4-fluoro-2-//(4-metoxy-2-pyridin-yl)methylsulphinyl/-1h-benzimidazole and process for obtaining
NO20011555L (no) Orale doseringsformuleringer omfattende (2S,3S,5R)-2-(3,5- difluorfenyl)-3,5-dimetyl-2-morfolinol og en effektivstabiliserende mengde alginsyre
FR2500303B1 (no)
BG105127A (en) Method for treament of nicotine addiction
EE200100196A (et) a-tsüklodekstriinil põhinevad farmatseutilised kompositsioonid LH-RH analoogide peroraalseks manustamiseks
SE8401968L (sv) Forfarande for framstellning av vel absorberbara orala lekemedelsdoseringsformer av medicinska 1,4-dihydropyridinderivat
GB9211277D0 (en) Pharmaceutical compositions
SE9803277D0 (sv) Novel compounds
UY26073A1 (es) Formas de dosis orales
IL134600A0 (en) Intermediates for naphthyl and dihydronaphthyl compounds, pharmaceutical compositions containing them and uses thereof as medicaments in the treatment of post-menopausal syndrome

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application